Provided by Tiger Trade Technology Pte. Ltd.

CervoMed

2.64
+0.07002.72%
Post-market: 2.660.0200+0.76%19:54 EDT
Volume:134.53K
Turnover:352.30K
Market Cap:39.91M
PE:-0.83
High:2.65
Open:2.55
Low:2.55
Close:2.57
52wk High:10.89
52wk Low:2.13
Shares:15.12M
Float Shares:9.60M
Volume Ratio:0.90
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1959
EPS(LYR):-2.9824
ROE:-107.62%
ROA:-60.80%
PB:1.74
PE(LYR):-0.89

Loading ...

CervoMed price target lowered to $7 from $9 at Roth Capital

TIPRANKS
·
Aug 20

CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 12

CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained

TIPRANKS
·
Aug 12

CervoMed is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Aug 10

CervoMed Q2 Net Loss Lower than Estimates as Costs Drop

Reuters
·
Aug 10

CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate

Benzinga Earnings
·
Aug 10

Press Release: CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Dow Jones
·
Aug 10

CervoMed Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 08

Cervomed Q2 FY26 Net Loss Widens 5% to $6.57 Million; Revenue Turns to None

Reuters
·
Aug 08

CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

GlobeNewswire
·
Aug 05

CervoMed Inc Expected to Post a Loss of 87 Cents a Share - Earnings Preview

Reuters
·
Aug 04

CervoMed’s neflamapimod gains UK Innovation Passport

TIPRANKS
·
Aug 04

CervoMed Says UK Grants ILAP Innovation Passport for Neflamapimod in Lewy Body Dementia

Reuters
·
Aug 04

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (Ilap) for Treatment of Dementia with Lewy Bodies (Dlb)

THOMSON REUTERS
·
Aug 04

Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 15

CervoMed advances neflamapimod strategy with new DLB data

TIPRANKS
·
Jul 15

Cervomed Reports New Phase 2b Data Supporting Neflamapimod 50 Mg TID Dose for Planned DLB Phase 3 Trial

Reuters
·
Jul 14

Cervomed Announces New Clinical, Plasma Biomarker and Imaging Data at Aaic 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (dlb)

THOMSON REUTERS
·
Jul 14

Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 13

Cervomed Price Target Maintained with a $25.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 09